PubMed Health⌕ Search

PubMed · 16076196

B(C6F5)3- vs Al(C6F5)3-derived metallocenium ion pairs. Structural, thermochemical, and structural dynamic divergences.

Abstract

The thermodynamic and structural characteristics of Al(C6F(5)3-derived vs B(C6F5)3-derived group 4 metallocenium ion pairs are quantified. Reaction of 1.0 equiv of B(C6F5)3 or 1.0 or 2.0 equiv of Al(C6F5)3 with rac-C2H4(eta5-Ind)2Zr(CH3)2 (rac-(EBI)Zr(CH3)2) yields rac-(EBI)Zr(CH3)(+)H3CB(C6)F5)(3)(-) (1a), rac-(EBI)Zr(CH3)+H3CAl(C6F5)(3)(-) (1b), and rac-(EBI)Zr2+[H3CAl(C6F5)3](-)(2) (1c), respectively. X-ray crystallographic analysis of 1b indicates the H3CAl(C6F5)(3)(-) anion coordinates to the metal center via a bridging methyl in a manner similar to B(C6F5)3-derived metallocenium ion pairs. However, the Zr-(CH3)(bridging) and Al-(CH3)(bridging) bond lengths of 1b (2.505(4) A and 2.026(4) A, respectively) indicate the methyl group is less completely abstracted in 1b than in typical B(C6F5)3-derived ion pairs. Ion pair formation enthalpies (DeltaH(ipf)) determined by isoperibol solution calorimetry in toluene from the neutral precursors are -21.9(6) kcal mol(-1) (1a), -14.0(15) kcal mol(-1) (1b), and -2.1(1) kcal mol(-1) (1b-->1c), indicating Al(C6F5)3 to have significantly less methide affinity than B(C6F5)3. Analogous experiments with Me2Si(eta5-Me4C5)(t-BuN)Ti(CH3)2 indicate a similar trend. Furthermore, kinetic parameters for ion pair epimerization by cocatalyst exchange (ce) and anion exchange (ae), determined by line-broadening in VT NMR spectra over the range 25-75 degrees C, are DeltaH++(ce) = 22(1) kcal mol(-1), DeltaS++(ce) = 8.2(4) eu, DeltaH++(ae) = 14(2) kcal mol(-1), and DeltaS++(ae) = -15(2) eu for 1a. Line broadening for 1b is not detectable until just below the temperature where decomposition becomes significant ( approximately 75-80 degrees C), but estimation of the activation parameters at 72 degrees C gives DeltaH++(ce) approximately 22 kcal mol(-1)and DeltaH++(ae) approximately 16 kcal mol(-1), consistent with the bridging methide being more strongly bound to the zirconocenium center than in 1a.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Nicholas G Stahl, Michael R Salata, Tobin J Marks. 2005-08-10. B(C6F5)3- vs Al(C6F5)3-derived metallocenium ion pairs. Structural, thermochemical, and structural dynamic divergences.. https://doi.org/10.1021/ja0429622

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗